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The nature of the intraterrninal compartments from which acetylchohne (ACh) is released following presy- 
naptic stimulation was investigated. This was pursued by examining the effects of the anticholinergic drug 
2-(4-phenylpiperidino)cyclohexanol (AH5183) on the release of newly synthesized [-‘H]ACh and of endoge- 
nous ACh from puritied cholinergic nerve terminals (synaptosomes) which were isolated from the electric 
organs of Torpedo. Preincubation of the synaptosomes, with AH5183 (l-10 pM), does not affect either the 
intraterminal synthesis of [JH]ACh or the uptake of its precursors, but results in a marked inhibition (85%) 
of the release of the newly synthesized [‘H]ACh. However, when AH5 183 is added following the accumula- 
tion of [3H]ACh in the nerve terminals, it does not affect [)H]ACh release. AH5183 also has no effect on 
the release of preformed endogenous ACh. These findings, together with the previous in vitro demonstra- 
tions that AH5183 is a potent inhibitor of ACh uptake into isolated cholinergic vesicles, suggest hat most 
of the synaptosomal ACh is secreted by a vesicular mechanism. 
AcetylchoIine Cholinergic synaptic vesicle 
1. INTRODUCTION 
The vesicular hypothesis, which asserts that 
quanta1 release of ACh from cholinergic nerve ter- 
minals arises from the fusion of synaptic vesicles 
with the presynaptic membrane (review [1,2]), has 
been challenged by the cytoplasmic theory accord- 
ing to which the presynaptic cytosol is the im- 
, mediate source of the released ACh [3-51. To 
resolve this controversy, it is pertinent that the 
ratio of vesicular to non-vesicular elease is deter- 
mined directly. This can be achieved by examining 
the effects on presynaptic release of compounds 
which specifically block ACh uptake into choliner- 
gic synaptic vesicles. 
Previous studies suggest hat the drug AH.5183, 
which causes neuromuscular blockade [6], inhibits 
ACh release by interfering with the storage of new- 
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ly synthesized ACh in cholinergic synaptic vesicles 
[7,8]. This assertion has recently been confirmed 
by Parsons and co-workers [9], who demonstrated 
that AH5183 is a potent inhibitor (IGO = 40 nM) 
of ACh uptake into isolated Torpedo synaptic 
vesicles and by Howard and collaborators who 
demonstrated that AH5183 inhibits the loading of 
ACh into storage vesicles in PC12 cells [lo] and 
blocks the evoked release of newly synthesized 
ACh from these cells [l 11. 
Here, we investigated the subcellular source of 
the ACh which is released from isolated Torpedo 
cholinergic nerve terminals (synaptosomes) by ex- 
amining the effects of AH5183 on the release of 
preformed and newly synthesized ACh. Our 
findings indicate that AH5 183 blocks the secretion 
of most of the releasable ACh (85%) which 
accumulated in the nerve terminals following the 
addition of the drug, but does not inhibit the 
release of the ACh which was formed prior to its 
addition. 
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2. EXPERIMENTAL 
2.1. Preparation and radiolabeling of Torpedo 
synaptosomes 
Torpedo ocellata were caught live off the coast 
of Tel Aviv during the autumn and winter and 
were maintained in seawater aquaria up to 2 
months prior to use. Cholinergic synaptosomes 
(fraction a2) were purified from the homogenates 
of fresh Torpedo electric organs as described [12]. 
The synaptosomes (1.5-2.0 mg protein/ml) were 
then diluted 2-fold with modified Torpedo buffer 
(modified TB:250 mM NaC1,4.8 mM KCl, 2.4 
mM MgC12, 0.1 mM EGTA, 10 mM glucose, 260 
mM sucrose, 1.2 mM Na phosphate buffer; pH 
7.2) and incubated at 25°C for 1 h. Radiolabeling 
was initiated by the addition of choline (10 PM), 
acetate (50 PM) and [3H]acetate (2 &i/ml), 
followed by a 75 min incubation at 25°C. The 
amount of [3H]acetate taken up by the nerve ter- 
minals was determined by filtration through GF/C 
filters as in [13]. The extent of intraterminal con- 
version of t3H]acetate to [3H]ACh was determined 
as follows: the radioactivity taken up by the synap- 
tosomes was extracted from the GF/C filters with 
3 ml of 0.1 M HCl (10 min at 9O”C), after which 
it was lyophilized and resuspended in 0.5 ml of 0.2 
M Na phosphate, pH 7.5. The [3H]ACh content of 
the lyophilizate was determined by the assay of 
Johnson and Russell [14] which is based on deter- 
mination of the partitioning of the radioactivity 
between an acidic buffer and a toluene-based scin- 
tillator prior to and following the addition of ex- 
ogenous acetylcholinesterase. The yield of this pro- 
cedure (> 9OVo) was determined utilizing an 
[3H]acetate-labeled [3H]ACh standard. When the 
effect of AH5183 on [3H]acetate uptake and 
[3H]ACh synthesis was examined it was added 15 
min before the radiolabeled precursor. Results 
presented are means f SD of the indicated number 
of experiments. 
2.2. Measurements of synaptosomal release of 
acetylcholine and FHJacetylcholine 
Release experiments were performed at 25°C in 
a continuous flow apparatus [15] in which synap- 
tosomes (0.5-0.7 mg protein) prelabeled with 
[3H]acetate were loaded onto a GF/C filter (What- 
man) mounted on a holder (25 mm diameter, 0.5 
ml volume) and washed with 20 ml modified TB 
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(flow rate 2 ml/min). A baseline was then estab- 
lished by flowing 5 ml modified TB (flow rate 1 
ml/min), which were collected in 0.5 ml fractions. 
Release was induced by flowing 8 ml K+-modified 
TB which contained 5 mM Ca2+, after which the 
synaptosomes were lysed by flowing 3 ml water. 
The K+ buffer was similar to modified TB, except 
that it contained 125 mM KC1 and 125 mM NaCl. 
In all the experiments the synaptosomes were load- 
ed onto the continuous flow apparatus 75 min 
after the initiation of radiolabeling and stimulated 
15 min later. 
The amounts of preformed endogenous ACh 
were measured by the chemiluminescence method 
developed by Israel and Lesbats [16], which is 
based on conversion of the choline, produced by 
hydrolysis of the released ACh, to betaine and 
Hz02 and detection of the latter by the luminol- 
peroxidase system. [3]ACh release was monitored 
by liquid scintillation spectrometry. Control ex- 
periments in which an [3H]acetate-labeled prepara- 
tion was treated with the acetylcholinesterase in- 
hibitor phospholine iodide (100 ,uM for 30 min) 
revealed that most of the released choline (> 75%) 
and [3H]acetate (>90%) moieties are secreted as 
ACh and [3H]acetate-ACh, respectively. Since the 
contribution of newly formed [3]ACh to the total 
ACh released is less than 1% [ 151, these measure- 
ments enable separate and parallel investigation of 
the effects of modulators on the release of en- 
dogenous ACh and radiolabeled [3]ACh. 
When the effect of AH5183 on release was ex- 
amined it was added to the preparation either 105 
min before stimulation (e.g. 15 min before the ad- 
dition of [3H]acetate) or 15 min prior to stimula- 
tion (e.g. 75 min after the initiation of radiolabel- 
ing) and was present throughout the release 
experiment. 
The ACh and [3H]ACh release data are 
presented as percent of total. The total was ob- 
tained by adding the amounts of synaptosomal 
neurotransmitter which were released by stimula- 
tion to those liberated subsequently by hypo- 
osmotic lysis. Results are the means + SD of the 
indicated number of experiments. Protein was 
determined according to Bradford [ 171. 
3. RESULTS 
Incubation of Torpedo synaptosomes with 
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[3H]acetate (50pM) and choline (10pM) resulted in 
the accumulation of radioactivity within the nerve 
terminals (716+ 162 pmol [3H]acetate/mg protein 
following a 75 min incubation, n = 5) and in the in- 
trasynaptosomal synthesis of [3H]ACh (510+ 102 
pmol/mg protein, n = 3). K+-depolarization of the 
labeled synaptosomes in the presence of Ca2+ (5 
mM) resulted in a rapid (ts/,= 1 min) Ca2+-depen- 
dent release of [3H]ACh (107k37 pmol/mg pro- 
tein, n = 5) and ACh (13.6 k 3 nmol/mg protein, 
n =5) which corresponded respectively to 
14.9-t5% of the accumulated radioactivity and 
13.8 f 3% of the endogenous synaptosomal ACh 
(fig. 1). 
w 21)- 
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Fig. 1. The effect of preincubation of purified Torpedo 
synaptosomes with AH5 183 on the release of newly syn- 
thesized [3H]ACh (A) and of preformed endogenous 
ACH (B). AH5183 (5 ,uM) was added to the synap- 
tosomes 15 min prior to the addition [3H]acetate (50pM) 
and choline (10 FM). The synaptosomes were K+ (125 
mM) depolarized in the presence of Ca2+ (5 mM) 90 min 
after the addition of the radioactivity and the resulting 
[3H]ACh and ACh release were measured as described in 
section 2. (0) Control; (a) synaptosomes preincubated 
Fig.2. The effect of AH5183 on [3H]ACh (A) and ACh 
(B) release from prelabeled Torpedo synaptosomes. The 
synaptosomes were labeled by incubation with 
[3H]acetate (50pM) and choline (1OpM) for 75 min after 
which they were loaded on to a continuous flow ap- 
paratus and stimulated at t = 90 min by K+ (125 mM) 
depolarization in the presence of Ca2+ (5 mM) as 
described in section 2. AH5183 (10 PM) was added 75 
min after the initiation of radiolabeling. (0) Control; 
with AH5183. (0) synaptosomes to which AH5183 was added. 
Incubation of the synaptosomes with AH5 183 (5 
PM) for 15 min prior to the addition of [3H]acetate 
and choline resulted in a marked reduction of 
[3H]ACh release to 15 + 4% of control (n = 5) but 
had no effect on the release of preformed en- 
dogenous ACh (98 rt 19% of control, n = 4) (fig. 1). 
Similar inhibitions were observed when the synap- 
tosomes were incubated with AH5183 (5 ,uM) for a 
longer duration (30 min) prior to the addition of 
[3H]acetate, and when either 10 PM or 1 FM 
AH5 183 was utilized. 
By contrast, when AH5183 (10pM) was added 
to prelabeled nerve terminals (75 min after the ad- 
391 
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Table 1 
Effects of AH5183 on uptake of [3H]acetate and 
synthesis of [3H]acetylcholine by Torpedo synaptosomes 
Control AH5183 
(pmol/mg protein) (Yo of control) 
[3H]Acetate uptake 716+ 162 97?8 
(n=5) (n=3) 
[3H]Acetylcholine 510* 102 106& 15 
synthesis (n=3) (n=3) 
[3H]Acetate uptake and [3H]acetylcholine synthesis 
following incubation (75 min at 25OC) of purified 
Torpedo synaptosomes with [3H]acetate (50 PM) and 
choline (1OpM) were measured as described in section 2. 
AH5183 (5 PM) was added to the preparation 15 min 
prior to the initiation of uptake. Results presented are 
the means + SD of the indicated number of experiments 
dition of [3H]acetate and 15 min prior to K+ 
depolarization) it had no effect on the release of 
either [3H]ACh (101 f 14% of control, n =4) or 
ACh (95 +5% of control, n= 3) (fig.2). Similar 
results were obtained when the effect of 20 FM 
AH5183 was examined and when the prelabeled 
preparation was incubated with AH5183 (l-10 
PM) for a longer duration (30 min) prior to release 
(not shown). 
The possibility that the selective inhibition of 
13H]ACh release induced by preincubation with 
AH5183 is due to a decrease in [3H]acetate uptake 
and [3H]ACh synthesis was examined by determin- 
ing the effects of the drug on these processes. As 
shown in table 1, addition of AH5183 (5 PM) prior 
to the initiation of radiolabeling had no effect 
either on [3H]acetate uptake or on its intrasynapto- 
somal conversion to [3H]ACh (97+8 and 
106rt 15% of the respective controls, n = 3). 
4. DISCUSSION 
Our findings show that preincubation of choli- 
nergic nerve terminals with AH5183 inhibits the 
release of most of the [‘H]ACh which is synthe- 
sized subsequently (85%), but that release is unaf- 
fected when AH5183 is added following the ac- 
cumulation of [3H]ACh in the nerve terminal. The 
concentrations of AH5183 which were examined 
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and found to have no effect on the release of 
preformed [3H]ACh (l-20 yM) are up to 20-fold 
higher than those which inhibit release maximally 
when added prior to the accumulation of [3H]ACh 
(2 1 PM). This observation together with the find- 
ing that the release of preformed [3H]ACh is unaf- 
fected even by prolonged incubations with 
AH5183 (30 min) imply that the observed time 
dependence of the effects of AH5183 on release is 
due to an intrinsic intraterminal process and not to 
the kinetics of the interaction of the drug with its 
target. 
The known inhibitory effect of AH5183 on ACh 
uptake into isolated Torpedo synaptic vesicles [9] 
and the present finding that it does not affect 
either the intraterminal synthesis of ACh or the up- 
take of its precursors (table 1) suggest that AH5 183 
blocks synaptosomal release by inhibiting the 
translocation of ACh from the presynaptic cytosol 
into synaptic vesicles. Thus, most of the release 
(85%) is vesicular. The finding that AH5183 does 
not affect the release of preformed endogenous as 
well as radiolabeled ACh (figs.lB,2B), is consis- 
tent with this interpretation in that under these 
conditions the neurotransmitter has presumably 
been taken up by the vesicles prior to the addition 
of the drug. 
The mechanisms underlying the release of the 
[3H]ACh pool which is not inhibited by preincuba- 
tion with AH5 183 (15vo) are not known. However, 
since it is not affected even by prolonged prein- 
cubation (up to 30 min) with high concentration 
(I-1OpM) of AH5183, it seems that this release is 
indeed mediated by ae different, presumably non- 
vesicular, mechanism. It is of interest to note that 
saturating levels of anticytoskeletal drugs also in- 
hibit the release of about 80% of the releasable 
[3H]ACh [18]. It is therefore tempting to suggest 
that cytoskeleton-disrupting drugs affect vesicular 
but not non-vesicular release. 
The experimental approach which was under- 
taken here can be extended for the study of the rate 
of translocation of cytosolic ACh into synaptic 
vesicles. Indeed, preliminary findings (in prepara- 
tion) which were obtained by examining the 
kinetics of the effects of AH5183 on Torpedo 
synaptosomes suggest that the transport of 
[3H]ACh from the presynaptic cytosol into synap- 
tic vesicles is relatively slow and lags behind its 
synthesis. 
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